Eli Lilly and Novo Nordisk will continue to compete over the glucagon-like peptide 1 receptor agonist (GLP-1RA) market, with the strong possibility that the two pharmaceutical giants will completely own the space due to the current lack of other marketed competitors, including biosimilars. The two giants will likely push out the remaining competition, namely AstraZeneca’s exenatide franchise, says GlobalData, a leading data and analytics company.
At the 81st Scientific Sessions of the American Diabetes Association (ADA) annual meeting, data was presented on a variety of antidiabetics that fall under the GLP-1RA umbrella, including Eli Lilly’s tirzepatide, Novo …
Related posts:
It’s raining tech unicorns in India with increasing digital adoption, says GlobalData
Netherlands on track to phase out coal power by 2030, says GlobalData
New low-cost start-up Bonza Airlines set to fill void in Australia’s domestic routes, says GlobalDat...
Reduced risk of CV morbidity and mortality demonstrated in FIGARO-DKD study
